Neogenomics (NEO) Current Assets (2010 - 2026)

Neogenomics (NEO) has reported Current Assets for 17 consecutive years, with $381.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 2.82% year-over-year to $381.5 million; the trailing twelve-month figure through Jun 2026 stood at $381.5 million (down 2.82% YoY), and the FY2025 full-year result was $376.3 million, down 36.87% from the prior year.
• Current Assets climbed to $381.5 million in Q2 2026 per NEO's latest filing, from $373.7 million in the prior quarter.
• Across five years, Current Assets topped out at $651.1 million in Q1 2022 and bottomed at $373.7 million in Q1 2026.
• Historically, Current Assets has averaged $536.7 million across 5 years, with a median of $584.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Current Assets increased 0.56% in 2024, then plunged 36.87% in 2025.
• Over 5 years, Current Assets stood at $605.3 million in 2022, then retreated by 1.4% to $596.8 million in 2023, then retreated by 0.13% to $596.0 million in 2024, then slumped by 36.87% to $376.3 million in 2025, then climbed by 1.38% to $381.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $381.5 million, $373.7 million, and $376.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.